• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MannKind Corporation - Common Stock (NQ:MNKD)

    5.525 -0.015 (-0.27%)
    Streaming Delayed Price Updated: 12:55 PM EST, Feb 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 721,958
    Open 5.510
    Bid (Size) 5.520 (4,000)
    Ask (Size) 5.530 (1,400)
    Prev. Close 5.540
    Today's Range 5.490 - 5.585
    52wk Range 3.381 - 6.510
    Shares Outstanding 264,305,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
    Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D 
    From MannKind
    Via GlobeNewswire

    Performance

    YTD
    -1.3%
    -1.3%
    1 Month
    +0.6%
    +0.6%
    3 Month
    +9.2%
    +9.2%
    6 Month
    +39.5%
    +39.5%
    1 Year
    +1.9%
    +1.9%

    More News

    Read More
    News headline image
    Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
    Via Stocktwits
    MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
    Via Stocktwits
    MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
    Via Stocktwits
    MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
    Via Stocktwits
    MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
    Via Stocktwits
    News headline image
    MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
    From MannKind
    Via GlobeNewswire
    News headline image
    Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    MannKind Provides Business Updates and 2026 Growth Drivers
    From MannKind
    Via GlobeNewswire
    News headline image
    Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    MannKind Shares FUROSCIX® Business Updates
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Present at the Jefferies Global Healthcare Conference
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗
    Via Chartmill
    Topics Earnings
    News headline image
    MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
    From MannKind
    Via GlobeNewswire

    Frequently Asked Questions

    Is MannKind Corporation - Common Stock publicly traded?
    Yes, MannKind Corporation - Common Stock is publicly traded.
    What exchange does MannKind Corporation - Common Stock trade on?
    MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MannKind Corporation - Common Stock?
    The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
    What is the current price of MannKind Corporation - Common Stock?
    The current price of MannKind Corporation - Common Stock is 5.525
    When was MannKind Corporation - Common Stock last traded?
    The last trade of MannKind Corporation - Common Stock was at 02/18/26 12:55 PM ET
    What is the market capitalization of MannKind Corporation - Common Stock?
    The market capitalization of MannKind Corporation - Common Stock is 1.46B
    How many shares of MannKind Corporation - Common Stock are outstanding?
    MannKind Corporation - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.